FDA declines to approve Corcept's rare disorder drug

FDA declines to approve Corcept's rare disorder drug

As the celebrations for the end of 2025 gathered pace, the FDA delivered a year-end blow to Corcept by turning down its new Cushing's drug.

Why Corcept Therapeutics stock crashed today and what comes next?

Corcept Therapeutics (NASDAQ: CORT) crashed about 50% on Dec. 31 after the FDA requested additional data to support the efficacy of relacorilant, its candidate treatment for Cushing’s syndrome. The setback cast doubt on CORT’s pipeline strength and triggered a sharp re-evaluation by analysts. It underscores the market’s sensitivity to regulatory developments in small-cap drug makers. Following today’s plunge, Corcept stock is down 70% versus its…

FDA rejects relacorilant for Cushing's-related high blood pressure

The U.S. Food and Drug Administration (FDA) has declined to approve relacorilant, an experimental oral therapy for patients with Cushing’s syndrome experiencing high blood pressure. In a complete response letter, the agency stated that current data do not yet conclusively show that the treatment’s benefits outweigh its risks. The decision comes as a setback for developer Corcept Therapeutics, which had sought approval for the drug to treat endog…

Kaplan Fox Announces an Investigation Into Corcept Therapeutics, Inc. (CORT) for Potential Securities Law Violations

Open the article to view the coverage from NewMediaWire